|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,485.00 JPY | +7.22% |
|
-0.93% | +4.87% |
| 03-26 | Renascience Inc. cancelled the transaction announced on November 28, 2025 | CI |
| 03-05 | Renascience Inc. announced that it has received ¥459.972744 million in funding from CVI Investments, Inc. | CI |
| Market Cap | 20.46B 128M 112M 104M 95.37M 180M 12.26B 183M 1.22B 481M 6.1B 482M 472M | P/E 2025 |
118x | P/E 2026 | -71.8x |
|---|---|---|---|---|---|
| Enterprise Value | 17.06B 107M 93.05M 86.6M 79.51M 150M 10.22B 152M 1.02B 401M 5.09B 402M 393M | EV / Sales 2025 |
87.3x | EV / Sales 2026 | 290x |
| Free-Float |
47.66% | Yield 2025 * |
-
| Yield 2026 | - |
| 1 day | +7.22% | ||
| 1 week | -0.93% | ||
| 1 month | -1.66% | ||
| 3 months | +23.65% | ||
| 6 months | +0.34% | ||
| Current year | +4.87% |
| 1 week | 1,379 |  | 1,549 |
| 1 month | 1,379 | | 1,771 |
| Current year | 1,108 | | 2,185 |
| 1 year | 1,108 | | 3,170 |
| 3 years | 263 | | 3,310 |
| 5 years | 263 | | 3,310 |
| 10 years | 263 | | 3,310 |
| Manager | Title | Age | Since |
|---|---|---|---|
Keisuke Furuta
PSD | President | 38 | 01/06/2024 |
Sho Kato
CTO | Chief Tech/Sci/R&D Officer | 38 | 01/06/2021 |
Kahoru Hori
IRC | Investor Relations Contact | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Toshio Miyata
CHM | Chairman | 65 | 01/04/2020 |
Sho Kato
BRD | Director/Board Member | 38 | 01/06/2021 |
Keisuke Furuta
BRD | Director/Board Member | 38 | 01/06/2024 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +7.22% | -0.93% | -50.10% | +196.41% | 128M | |
| -0.53% | -3.95% | +50.70% | +153.56% | 1,024B | |
| +0.21% | -2.68% | +53.20% | +51.79% | 618B | |
| -2.51% | -3.25% | +28.54% | +68.94% | 443B | |
| +0.06% | -0.42% | +37.53% | +30.67% | 349B | |
| -0.69% | -0.30% | +13.76% | +12.83% | 264B | |
| -7.37% | -4.40% | -0.74% | -44.28% | 209B | |
| -0.64% | +2.43% | +29.74% | +65.93% | 208B | |
| -0.82% | +0.70% | +15.05% | +72.05% | 162B | |
| +0.40% | +1.92% | +6.47% | -29.77% | 143B | |
| Average | -0.47% | -1.19% | +18.41% | +57.81% | 341.9B | |
| Weighted average by Cap. | -1.00% | -2.02% | +36.14% | +71.91% |
| 2025 | 2026 | |
|---|---|---|
| Net sales | 132M 828K 720K 670K 615K 1.16M 79.07M 1.18M 7.9M 3.1M 39.37M 3.11M 3.04M | 68M 427K 371K 345K 317K 599K 40.73M 608K 4.07M 1.6M 20.28M 1.6M 1.57M |
| Net income | 113M 709K 616K 574K 527K 995K 67.69M 1.01M 6.76M 2.65M 33.7M 2.66M 2.6M | -301M -1.89M -1.64M -1.53M -1.4M -2.65M -180M -2.69M -18.01M -7.07M -89.77M -7.09M -6.94M |
| Net Debt | -1.8B -11.29M -9.81M -9.13M -8.39M -15.84M -1.08B -16.08M -108M -42.26M -537M -42.4M -41.47M | -3.4B -21.35M -18.56M -17.27M -15.86M -29.95M -2.04B -30.41M -204M -79.91M -1.01B -80.18M -78.41M |
Employees
-
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/07/26 | ¥1,485.00 | +7.22% | 267,300 |
| 30/07/26 | ¥1,385.00 | -3.28% | 228,500 |
| 29/07/26 | ¥1,432.00 | -4.09% | 255,900 |
| 28/07/26 | ¥1,493.00 | -3.37% | 142,700 |
| 27/07/26 | ¥1,545.00 | +3.07% | 159,600 |
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4889 Stock
Select your edition
All financial news and data tailored to specific country editions
